vs
Emergent BioSolutions Inc.（EBS）与Repay Holdings Corp（RPAY）财务数据对比。点击上方公司名可切换其他公司
Emergent BioSolutions Inc.的季度营收约是Repay Holdings Corp的1.9倍（$148.7M vs $78.6M），Emergent BioSolutions Inc.净利率更高（-36.7% vs -178.3%，领先141.6%），Repay Holdings Corp同比增速更快（0.4% vs -23.6%），Emergent BioSolutions Inc.自由现金流更多（$73.8M vs $23.2M），过去两年Repay Holdings Corp的营收复合增速更高（-1.3% vs -29.6%）
Emergent BioSolutions是一家总部位于美国马里兰州盖瑟斯堡的跨国专业生物制药企业，公司专注于开发针对传染病及阿片类药物过量的疫苗与抗体疗法，同时还为生物防御领域提供相关医疗设备支持。
Repay Holdings Corp是一家聚焦北美市场的支付技术服务商，为零售、医疗、汽车服务、电商等领域的企业提供整合支付处理方案，涵盖银行卡收单、ACH转账、POS系统集成等数字化支付工具，助力客户简化交易流程、提升运营效率。
EBS vs RPAY — 直观对比
营收规模更大
EBS
是对方的1.9倍
$78.6M
营收增速更快
RPAY
高出24.0%
-23.6%
净利率更高
EBS
高出141.6%
-178.3%
自由现金流更多
EBS
多$50.6M
$23.2M
两年增速更快
RPAY
近两年复合增速
-29.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $148.7M | $78.6M |
| 净利润 | $-54.6M | $-140.1M |
| 毛利率 | 42.9% | 74.2% |
| 营业利润率 | -18.8% | -182.2% |
| 净利率 | -36.7% | -178.3% |
| 营收同比 | -23.6% | 0.4% |
| 净利润同比 | -74.4% | -3304.1% |
| 每股收益（稀释后） | $-0.95 | $-1.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBSRPAY
| Q4 25 | $148.7M | $78.6M | ||
| Q3 25 | $231.1M | $77.7M | ||
| Q2 25 | $140.9M | $75.6M | ||
| Q1 25 | $222.2M | $77.3M | ||
| Q4 24 | $194.7M | $78.3M | ||
| Q3 24 | $293.8M | $79.1M | ||
| Q2 24 | $254.7M | $74.9M | ||
| Q1 24 | $300.4M | $80.7M |
净利润EBSRPAY
| Q4 25 | $-54.6M | $-140.1M | ||
| Q3 25 | $51.2M | $-6.4M | ||
| Q2 25 | $-12.0M | $-102.3M | ||
| Q1 25 | $68.0M | $-7.9M | ||
| Q4 24 | $-31.3M | $-4.1M | ||
| Q3 24 | $114.8M | $3.2M | ||
| Q2 24 | $-283.1M | $-4.1M | ||
| Q1 24 | $9.0M | $-5.2M |
毛利率EBSRPAY
| Q4 25 | 42.9% | 74.2% | ||
| Q3 25 | 62.8% | 74.4% | ||
| Q2 25 | 52.5% | 75.7% | ||
| Q1 25 | 60.2% | 75.9% | ||
| Q4 24 | 39.4% | 76.3% | ||
| Q3 24 | 54.9% | 77.8% | ||
| Q2 24 | -18.8% | 78.2% | ||
| Q1 24 | 49.2% | 76.2% |
营业利润率EBSRPAY
| Q4 25 | -18.8% | -182.2% | ||
| Q3 25 | 33.1% | -3.9% | ||
| Q2 25 | 1.1% | -138.7% | ||
| Q1 25 | 22.5% | -4.7% | ||
| Q4 24 | -4.9% | -1.5% | ||
| Q3 24 | 22.0% | -0.9% | ||
| Q2 24 | -79.9% | -4.6% | ||
| Q1 24 | 13.2% | -3.1% |
净利率EBSRPAY
| Q4 25 | -36.7% | -178.3% | ||
| Q3 25 | 22.2% | -8.3% | ||
| Q2 25 | -8.5% | -135.2% | ||
| Q1 25 | 30.6% | -10.3% | ||
| Q4 24 | -16.1% | -5.3% | ||
| Q3 24 | 39.1% | 4.1% | ||
| Q2 24 | -111.2% | -5.4% | ||
| Q1 24 | 3.0% | -6.5% |
每股收益（稀释后）EBSRPAY
| Q4 25 | $-0.95 | $-1.68 | ||
| Q3 25 | $0.91 | $-0.08 | ||
| Q2 25 | $-0.22 | $-1.15 | ||
| Q1 25 | $1.19 | $-0.09 | ||
| Q4 24 | $-0.45 | $-0.04 | ||
| Q3 24 | $2.06 | $0.03 | ||
| Q2 24 | $-5.38 | $-0.04 | ||
| Q1 24 | $0.17 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $205.4M | $115.7M |
| 总债务越低越好 | $589.7M | $280.1M |
| 股东权益账面价值 | $522.6M | $484.4M |
| 总资产 | $1.3B | $1.2B |
| 负债/权益比越低杠杆越低 | 1.13× | 0.58× |
8季度趋势，按日历期对齐
现金及短期投资EBSRPAY
| Q4 25 | $205.4M | $115.7M | ||
| Q3 25 | $245.5M | $95.7M | ||
| Q2 25 | $267.3M | $162.6M | ||
| Q1 25 | $149.1M | $165.5M | ||
| Q4 24 | $99.5M | $189.5M | ||
| Q3 24 | $149.9M | $168.7M | ||
| Q2 24 | $69.7M | $147.1M | ||
| Q1 24 | $78.5M | $128.3M |
总债务EBSRPAY
| Q4 25 | $589.7M | $280.1M | ||
| Q3 25 | $693.1M | $279.5M | ||
| Q2 25 | $700.0M | $279.0M | ||
| Q1 25 | $700.0M | $497.6M | ||
| Q4 24 | $700.0M | $496.8M | ||
| Q3 24 | $700.8M | $496.2M | ||
| Q2 24 | $863.8M | $435.6M | ||
| Q1 24 | $909.2M | $434.9M |
股东权益EBSRPAY
| Q4 25 | $522.6M | $484.4M | ||
| Q3 25 | $582.5M | $616.9M | ||
| Q2 25 | $536.2M | $633.7M | ||
| Q1 25 | $552.7M | $755.7M | ||
| Q4 24 | $482.8M | $761.3M | ||
| Q3 24 | $508.4M | $754.7M | ||
| Q2 24 | $386.3M | $815.4M | ||
| Q1 24 | $663.9M | $813.8M |
总资产EBSRPAY
| Q4 25 | $1.3B | $1.2B | ||
| Q3 25 | $1.5B | $1.3B | ||
| Q2 25 | $1.4B | $1.4B | ||
| Q1 25 | $1.4B | $1.5B | ||
| Q4 24 | $1.4B | $1.6B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.5B | $1.5B | ||
| Q1 24 | $1.8B | $1.5B |
负债/权益比EBSRPAY
| Q4 25 | 1.13× | 0.58× | ||
| Q3 25 | 1.19× | 0.45× | ||
| Q2 25 | 1.31× | 0.44× | ||
| Q1 25 | 1.27× | 0.66× | ||
| Q4 24 | 1.45× | 0.65× | ||
| Q3 24 | 1.38× | 0.66× | ||
| Q2 24 | 2.24× | 0.53× | ||
| Q1 24 | 1.37× | 0.53× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.7M | $23.3M |
| 自由现金流经营现金流 - 资本支出 | $73.8M | $23.2M |
| 自由现金流率自由现金流/营收 | 49.6% | 29.6% |
| 资本支出强度资本支出/营收 | 2.6% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $156.8M | $90.7M |
8季度趋势，按日历期对齐
经营现金流EBSRPAY
| Q4 25 | $77.7M | $23.3M | ||
| Q3 25 | $-2.3M | $32.2M | ||
| Q2 25 | $106.4M | $33.1M | ||
| Q1 25 | $-11.2M | $2.5M | ||
| Q4 24 | $-79.9M | $34.3M | ||
| Q3 24 | $153.7M | $60.1M | ||
| Q2 24 | $47.5M | $31.0M | ||
| Q1 24 | $-62.6M | $24.8M |
自由现金流EBSRPAY
| Q4 25 | $73.8M | $23.2M | ||
| Q3 25 | $-5.7M | $32.1M | ||
| Q2 25 | $103.5M | $33.0M | ||
| Q1 25 | $-14.8M | $2.4M | ||
| Q4 24 | $-81.6M | $34.0M | ||
| Q3 24 | $147.9M | $59.8M | ||
| Q2 24 | $42.9M | $30.5M | ||
| Q1 24 | $-73.4M | $24.7M |
自由现金流率EBSRPAY
| Q4 25 | 49.6% | 29.6% | ||
| Q3 25 | -2.5% | 41.3% | ||
| Q2 25 | 73.5% | 43.6% | ||
| Q1 25 | -6.7% | 3.0% | ||
| Q4 24 | -41.9% | 43.5% | ||
| Q3 24 | 50.3% | 75.6% | ||
| Q2 24 | 16.8% | 40.7% | ||
| Q1 24 | -24.4% | 30.6% |
资本支出强度EBSRPAY
| Q4 25 | 2.6% | 0.1% | ||
| Q3 25 | 1.5% | 0.2% | ||
| Q2 25 | 2.1% | 0.1% | ||
| Q1 25 | 1.6% | 0.2% | ||
| Q4 24 | 0.9% | 0.3% | ||
| Q3 24 | 2.0% | 0.3% | ||
| Q2 24 | 1.8% | 0.6% | ||
| Q1 24 | 3.6% | 0.1% |
现金转化率EBSRPAY
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.16× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.34× | 18.52× | ||
| Q2 24 | — | — | ||
| Q1 24 | -6.96× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
RPAY
| Sales Channel Directly To Consumer | $69.4M | 88% |
| Other | $6.8M | 9% |
| Sales Channel Through Intermediary | $2.3M | 3% |
